Merck Subsidiary Seeks Expanded Operations in Japan (Japan)
This article was originally published in PharmAsia News
Merck Serono International plans several projects this year to expand its presence in the Japanese market, including beginning trials in the country for a new cancer drug developed in Japan. The subsidiary of German-based Merck KgaA says it will file soon for approval of its Gonal-f (follitropin alfa/beta) fertility treatment that relies on gene-splicing technology. The company also expects approval for marketing its Erbitux (cetuximab) colorectal cancer drug in Japan this year. The Merck Serono expansion in Japan comes at a time other foreign drug makers are cutting back on their operations in the country. (Click here for more - may require a subscription
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.